Incyte Corporation (INCY)
63
  • CONTENT
  • SOURCES
Incyte meldet vielversprechende Ergebnisse der Phase-2-Studie mit Retifanlimab (INCMGA0012) bei Patienten mit zuvor behandeltem fortgeschrittenem Plattenepithelkarzinom des Analkanals
WILMINGTON (US-Bundesstaat Delaware)--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) gab heute die Ergebnisse der Phase-2-Studie POD1UM-202 zur Untersuchung von Retifanlimab, einem PD-1-Inhibitor, bei zuvor behandelten Patienten mit fortgeschrittenem Plattenepithelkarzinom des Analkanals (SCAC) bekannt, bei denen es nach einer platinbasierten Standard-Chemotherapie zu einer Progression gekommen ist. Für die Studie wurden 94 Patienten rekrutiert, darunter Patienten mit gut kontrollierter HIV-Infektion (1
Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal
WILMINGTON, Del.--(BUSINESS WIRE)--Encouraging Results from Phase 2 Trial of Retifanlimab in Patients with Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal
Incyte and MorphoSys to Host Investor Event to Discuss the Unmet Need and Global Opportunities for Tafasitamab in Non-Hodgkin Lymphomas
Incyte and MorphoSys to Host Investor Event to Discuss the Unmet Need and Global Opportunities for Tafasitamab in Non-Hodgkin Lymphomas
Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial
INDIANAPOLIS, Sept. 14, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today initial data emerging from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the…
Incyte Announces Recipient of the Inaugural Incyte Ingenuity Award to Recognize Innovative Solutions that Address Needs in the GVHD Community
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that Massachusetts General Cancer Center is the recipient of the first Incyte Ingenuity Award, an annual program that was created to support people living with graft-versus-host disease (GVHD) by encouraging innovative and novel solutions that address specific challenges facing the GVHD community. Massachusetts General Cancer Center has been awarded $100,000 to implement its project, Horizon Mobile App for Patients with Chr
National Comprehensive Cancer Network® Adds Monjuvi® (tafasitamab-cxix) to its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
PLANEGG, Germany & MUNICH & WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--National Comprehensive Cancer Network Adds Monjuvi® (tafasitamab-cxix) to its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
NIH to test remdesivir with Merck KGaA's interferon therapy as a COVID-19 treatment
The National Institutes of Health said it will conduct a randomized, controlled clinical trial testing a combination of Gilead Sciences Inc.'s remdesivir with Merck KGaA's interferon beta-1a as a treatment for COVID-19 patients. The study plans to enroll 1,000 people who have been hospitalized because of a COVID-19 infection. The federal agency said it expects to have preliminary results in the fall. Since the Food and Drug Administration granted an emergency use authorization to remdesivir in May, several clinical trials have been initiated that aim to pair the investigational therapy with other drugs to see if the combination can better treat severely ill COVID-19 patients. This includes another NIH trial pairing remdesivir with Eli Lilly & Co. and Incyte Corp. 's Olumiant. Roche Holding AG has also said it will test its rheumatoid arthritis drug in combination with remdesivir.
Incyte earnings beat estimates - Delaware Business Now
Incyte Corp. reported strong second-quarter earnings, while posting a loss for the first half, due to upfront costs related to an agreement with a German pharma company. Incyte is based near Wilmington. “We continue to execute successfully across all aspects our business,” stated Hervé Hoppenot, CEO of Incyte. For the first half, Incyte recorded an […]
Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #earnings--Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flow continued to pour in, with big pharma tie-ups flaunting positive tidings. In the biggest ever coronavirus funding deal, the Sanofi SA (NASDAQ: SNY ) GlaxoSmithKline plc (NYSE: GSK ) won a joint $2.1 billion U.S. federal funding award. Here're the key catalysts for the unfolding week: Conferences 72nd National Hemophilia Foundation's Annual Bleeding Disorders Meeting 2020 (virtual meeting): Aug. 1-8 PDUFA Dates FDA is scheduled to rule on DBV TECHNOLOGIE/S' ADR (NASDAQ: DBVT ) Viaskin peanut allergy patch Wednesday. However, cancellation of the Adcom meeting scheduled May 15 has poured cold water on the prospects of an approval coming through. Trevena Inc (NASDAQ: TRVN ) has a tryst with the FDA Friday, with respect to the NDA for its pain drug oleceridine, which was once rejected by the agency on the premise of inadequacy of clinical data.
Incyte Corporation (INCY): Will The Stock Price Recover?
Incyte Corporation (NASDAQ: INCY) was down by more than 19% earlier in today's trading. What is the stock price forecast (prediction)?
Top 6 Biotech Stocks For Traders
If you’re up for some speculative biotech trades, we are presenting the top 6 among our freshest picks of biotech stocks for the coming 12 months.
Follow Us